Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1B USD, Entering the U.S. Market and Consolidating Its Leadership in Brain Health and Rare Disease
Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, announce that they have entered into a definitive agreement pursuant to which […]
